Browse the evidence

Newer obesity management medications (OMMs), specifically semaglutide (2.4 mg) and tirzepatide (10-15 mg), demonstrate high efficacy comparable to metabolic bariatric surgery (MBS) in the short term (26-52 weeks), with tirzepatide achieving >15% TBWL.

For those seeking non-surgical weight loss, newer medications like semaglutide (2.4 mg) and tirzepatide (10-15 mg) are the most effective options available, with tirzepatide showing short-term weight loss (15.2%) comparable to surgical procedures. These require weekly administration and are generally more effective than older medications like orlistat. They are best used in conjunction with lifestyle interventions.

Tirzepatide demonstrates greater comparative weight loss and metabolic benefits than semaglutide in real-world observational studies, particularly in patients without pre-existing diabetes.

If you are using Semaglutide and not achieving your weight loss goals, switching to Tirzepatide may result in greater weight loss and better metabolic outcomes, especially if you do not have Type 2 Diabetes. Real-world data suggests Tirzepatide is more potent than Semaglutide in routine practice.

Combining GLP-1 receptor agonists (GLP-1RAs) with lifestyle modifications results in significantly greater weight loss and improved cardiometabolic biomarkers compared to lifestyle modifications alone in adults with overweight or obesity.

If you have overweight or obesity, combining a GLP-1 receptor agonist (like semaglutide or liraglutide) with lifestyle changes (calorie restriction and regular exercise) is significantly more effective for weight loss and improving heart health markers than lifestyle changes alone. To minimize muscle loss, ensure your lifestyle intervention includes resistance training. Consult a doctor to determine if GLP-1RAs are appropriate for you.

Treatment with tirzepatide (10 or 15 mg) produces a significantly greater reduction in predicted 10-year cardiovascular disease (CVD) risk compared to semaglutide (1.7 or 2.4 mg) in individuals with obesity without diabetes or prior CVD.

If you have obesity and are at risk for heart disease but don't have diabetes, tirzepatide may offer better long-term heart protection than semaglutide. It is taken as a weekly injection and has been shown to reduce your predicted 10-year risk of cardiovascular events more than semaglutide. Discuss with your doctor if this medication is appropriate for your specific health profile.

Tirzepatide treatment produces significant body weight, waist circumference, and waist-to-height ratio reductions in women across all reproductive stages (premenopausal, perimenopausal, and postmenopausal), demonstrating efficacy irrespective of menopausal status.

If you are a woman with overweight or obesity, whether you are premenopausal, perimenopausal, or postmenopausal, tirzepatide (15mg weekly) is highly effective for significant weight loss. Do not assume your reproductive stage limits your ability to lose weight with this treatment; the data shows robust results across all stages.

Tirzepatide 15 mg once weekly produces statistically significant greater reductions in body weight, BMI, and HbA1c compared to semaglutide 2.4 mg once weekly in patients with type 2 diabetes and obesity/overweight.

For patients with type 2 diabetes and obesity, tirzepatide 15mg once weekly is a more effective option for weight loss and blood sugar control than semaglutide 2.4mg. This treatment must be combined with a reduced-calorie diet and regular physical activity. Patients should be aware that while tirzepatide 15mg is more effective, it may have a slightly higher risk of gastrointestinal side effects compared to semaglutide 10mg, though both are generally well-tolerated.

Tirzepatide 15 mg provides statistically significant improvements in cardiometabolic risk factors, including waist circumference, fasting plasma glucose, and triglycerides, compared to semaglutide 2.4 mg.

Beyond weight loss, tirzepatide 15mg offers superior benefits for heart health markers like waist size, blood sugar (fasting), and triglycerides compared to semaglutide 2.4mg. This makes it a strong option for patients concerned about cardiovascular risk factors associated with obesity and diabetes.

Tirzepatide 15 mg once weekly is preferred for individuals with obesity and heart failure with preserved ejection fraction (HFpEF) to improve symptoms and functional capacity, irrespective of glycemic status or weight loss magnitude.

If you have obesity and heart failure with preserved ejection fraction (HFpEF), tirzepatide 15 mg once weekly is a preferred treatment to significantly reduce hospitalizations and improve your ability to walk and feel better, even if your blood sugar is normal or you don't lose a lot of weight.

Tirzepatide produces significantly greater weight loss than semaglutide in patients with type 2 diabetes, with a mean difference of -4.84 kg favoring tirzepatide.

If you have Type 2 Diabetes and are choosing between Tirzepatide and Semaglutide for weight loss, Tirzepatide is likely to produce greater weight loss (approx. 4.8 kg more on average). Both drugs share similar gastrointestinal side effect profiles, which are generally manageable. The choice may depend on individual response, tolerability, and cost/insurance coverage, but Tirzepatide shows superior efficacy in head-to-head comparisons.

GLP-1 and GIP receptor agonists (semaglutides and tirzepatides) effectively reverse overweight, obesity, and type 2 diabetes by targeting neuro-hormonal pathways, achieving mean weight reductions of 10.2% and 15.0% respectively, whereas lifestyle interventions fail to produce permanent weight loss due to compensatory biological mechanisms.

If you have struggled to maintain weight loss through diet and exercise alone, recognize that this is likely due to biological resistance (hormonal signals), not a lack of willpower. Consult a healthcare provider about GLP-1/GIP agonists (like semaglutide or tirzepatide), which target these specific pathways. While currently expensive, these treatments offer a clinically proven path to significant weight loss and diabetes management that lifestyle changes alone have failed to provide for most people.

Next-generation multi-receptor agonists (e.g., Tirzepatide, a dual GLP-1/GIP agonist) offer superior weight loss and metabolic efficacy compared to single GLP-1RAs.

If single GLP-1 medications (like Ozempic or Wegovy) aren't providing enough weight loss or metabolic improvement, ask your doctor about dual-agonists like Tirzepatide. These newer drugs target two hormones (GLP-1 and GIP) and have shown even greater weight loss in clinical trials. They are approved for both diabetes and obesity management.

GCGR/GLP-1 dual agonists (e.g., mazdutide, survodutide) and GCGR/GLP-1/GIP triple agonists (e.g., retatrutide) elicit substantial body weight reduction (up to 24.2%) and improve liver health in patients with obesity and MASLD/MASH.

For individuals with obesity and liver fat, newer once-weekly injections targeting the glucagon and GLP-1 receptors (and sometimes GIP) are showing remarkable results, with some patients losing over 20% of their body weight and seeing improvements in liver health. These are prescription medications requiring medical supervision, but they represent a significant advancement over older treatments.

Semaglutide (2.4 mg once-weekly) significantly reduces the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its components (steatosis, inflammation, ballooning) in patients with overweight/obesity and type 2 diabetes compared to placebo.

If you have overweight/obesity and type 2 diabetes, semaglutide (2.4 mg weekly) is a clinically proven treatment to significantly reduce liver fat, inflammation, and scarring (MASH/MASLD) compared to placebo. This is particularly relevant if lifestyle changes alone have not resolved liver issues. The treatment involves a weekly injection and is supported by strong statistical evidence from large clinical trials.

Retatrutide (12mg weekly) achieves 24.2% weight loss, rivaling bariatric surgery outcomes.

Retatrutide 12mg weekly can lead to ~24% weight loss. This is the highest efficacy reported in this review, rivaling surgery.

CagriSema (Cagrilintide + Semaglutide) achieves 22.7% weight loss, outperforming semaglutide alone.

CagriSema, a combination of Cagrilintide and Semaglutide, can lead to ~23% weight loss. It is more effective than Semaglutide alone.

Utilization of Glucagon-like peptide-1 (GLP-1) receptor agonists for Type 2 Diabetes is a significant independent predictor of achieving relevant weight loss (≥7%) in MASLD patients, with odds ratios increasing for greater weight loss thresholds.

If you have MASLD and Type 2 Diabetes, using a GLP-1 agonist significantly increases your chances of losing enough weight to improve your liver health. The data shows that users are over 4 times more likely to lose 10% or more of their body weight compared to non-users. Discuss this option with your doctor as part of a comprehensive MASLD management plan.

GLP-1 receptor agonists (GLP-1RAs) as adjunctive therapy to insulin significantly reduce body weight, HbA1c, and total daily insulin requirements in patients with type 1 diabetes and overweight or obesity.

If you have Type 1 Diabetes and are overweight, adding a GLP-1RA (like semaglutide or liraglutide) to your insulin regimen can help you lose weight (average 4-6 kg), lower your HbA1c slightly, and significantly reduce your daily insulin needs (by ~9 units). This is generally safe, though you may experience temporary nausea and a slightly higher risk of low blood sugar, which can be managed by adjusting your insulin dose.

Semaglutide demonstrates superior efficacy in reducing body weight, HbA1c, and insulin requirements compared to other GLP-1RAs (liraglutide, exenatide) in patients with Type 1 Diabetes.

Among GLP-1RAs, semaglutide (1.0 mg weekly) appears to be the most effective option for Type 1 Diabetes patients, offering greater weight loss (~6 kg) and insulin reduction (~15 units/day) compared to liraglutide or exenatide. Discuss with your provider if you are a candidate for this specific agent.

Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces dose-dependent reductions in body weight (up to 9.8% at 45 mg) and waist circumference, with maximal efficacy observed at higher doses (24-45 mg).

Orforglipron is an oral medication that helps obese adults lose weight and improve metabolic markers like blood sugar and cholesterol. It works by mimicking a natural hormone (GLP-1) to reduce appetite and slow digestion. The higher the dose (up to 45 mg daily), the more weight is lost, with studies showing up to 9.8% body weight reduction. However, higher doses also increase the risk of stomach issues like nausea and diarrhea, which may lead some patients to stop taking it. It is taken once daily without strict fasting requirements, making it more convenient than some injectable alternatives.

Treatment with semaglutide 2.4 mg for overweight or obesity leads to a statistically significant reduction in the need for concomitant antihypertensive and lipid-lowering medications compared to placebo, primarily through weight-loss-mediated improvements in blood pressure and lipid profiles.

If you are taking medication for high blood pressure or high cholesterol, significant weight loss achieved through semaglutide 2.4 mg may allow your doctor to safely lower your dose or stop the medication entirely. This is not automatic; it requires active monitoring by your healthcare provider to ensure your blood pressure and lipids remain in a healthy range without the drugs. Do not stop these medications on your own.

Phenotype-guided pharmacotherapy using naltrexone/bupropion extended-release (NB-ER) is the preferred treatment for obesity patients with emotional hunger, as it addresses both weight and depression symptoms.

If you struggle with emotional eating and depression, ask your doctor about NB-ER (naltrexone/bupropion). It is specifically shown to help with both weight loss and mood in this subgroup, unlike many standard antidepressants which may cause weight gain.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) are effective for weight loss in patients with obesity and may improve depression scores, with a low rate of adverse psychiatric events.

GLP-1 agonists (like Semaglutide or Tirzepatide) are highly effective for weight loss (15-21%) and may also improve depression. They have a low risk of psychiatric side effects. Discuss these with your doctor if you have no thyroid cancer history.

GLP-1 receptor agonists (semaglutide) and dual incretin agonists (tirzepatide) achieve 15-20% total body weight loss, rivaling the efficacy of bariatric surgery.

If you have obesity, these medications offer a powerful, non-surgical path to significant weight loss (15-20%). They require a weekly injection and likely lifelong use, but they can improve metabolic health and may be more accessible than surgery for some. Discuss with your doctor if you are a candidate.

GLP-1 receptor agonists (semaglutide and tirzepatide) produce significantly greater average weight loss (14.9% and 18.5%, respectively) than physicians estimate (9.22%), and are associated with high rates of gastrointestinal side effects (80-90%) that are significantly underestimated by prescribers.

If you are prescribing GLP-1 agonists, ensure you are counseling patients on the high likelihood of gastrointestinal side effects (up to 90%) and the significant magnitude of weight loss (15-18%). Underestimating these factors leads to poor adherence and unrealistic expectations.